Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Cash Flow (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Net Cash Flow data on record, last reported at -$13.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 184.91% year-over-year to -$13.0 million; the TTM value through Dec 2025 reached $53.9 million, down 11.6%, while the annual FY2025 figure was $53.9 million, 11.6% down from the prior year.
  • Net Cash Flow reached -$13.0 million in Q4 2025 per APLS's latest filing, down from $109.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $356.4 million in Q4 2021 and bottomed at -$298.4 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$4.9 million, with a median of -$9.9 million recorded in 2022.
  • The widest YoY moves for Net Cash Flow: up 3233.39% in 2023, down 717.05% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $356.4 million in 2021, then plummeted by 109.14% to -$32.6 million in 2022, then plummeted by 212.59% to -$101.8 million in 2023, then surged by 115.07% to $15.3 million in 2024, then crashed by 184.91% to -$13.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$13.0 million in Q4 2025, $109.1 million in Q3 2025, and $11.0 million in Q2 2025.